Research ExplorerPublicationsOrgan complications after CD19 CAR T-cell therapy for large ...

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

Standard

Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. / Penack, Olaf; Peczynski, Christophe; Koenecke, Christian; Polge, Emmanuelle; Sanderson, Robin; Yakoub-Agha, Ibrahim; Fegueux, Nathalie; Daskalakis, Michael; Collin, Matthew; Dreger, Peter; Kröger, Nicolaus; Schanz, Urs; Bloor, Adrian; Ganser, Arnold; Besley, Caroline; Wulf, Gerald G; Novak, Urban; Moiseev, Ivan; Schoemans, Hélène; Basak, Grzegorz W; Chabannon, Christian; Sureda, Anna; Glass, Bertram; Peric, Zinaida.

In: FRONT IMMUNOL, Vol. 14, 2023, p. 1252811.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Penack, O, Peczynski, C, Koenecke, C, Polge, E, Sanderson, R, Yakoub-Agha, I, Fegueux, N, Daskalakis, M, Collin, M, Dreger, P, Kröger, N, Schanz, U, Bloor, A, Ganser, A, Besley, C, Wulf, GG, Novak, U, Moiseev, I, Schoemans, H, Basak, GW, Chabannon, C, Sureda, A, Glass, B & Peric, Z 2023, 'Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party', FRONT IMMUNOL, vol. 14, pp. 1252811. https://doi.org/10.3389/fimmu.2023.1252811

APA

Penack, O., Peczynski, C., Koenecke, C., Polge, E., Sanderson, R., Yakoub-Agha, I., Fegueux, N., Daskalakis, M., Collin, M., Dreger, P., Kröger, N., Schanz, U., Bloor, A., Ganser, A., Besley, C., Wulf, G. G., Novak, U., Moiseev, I., Schoemans, H., ... Peric, Z. (2023). Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. FRONT IMMUNOL, 14, 1252811. https://doi.org/10.3389/fimmu.2023.1252811

Vancouver

Penack O, Peczynski C, Koenecke C, Polge E, Sanderson R, Yakoub-Agha I et al. Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. FRONT IMMUNOL. 2023;14:1252811. https://doi.org/10.3389/fimmu.2023.1252811

Bibtex

@article{a7743301eab74e8caff0daea1f1f2b87,
title = "Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party",
abstract = "We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.",
keywords = "Humans, Immunotherapy, Adoptive/adverse effects, Retrospective Studies, Receptors, Chimeric Antigen, Lymphoma, Large B-Cell, Diffuse/etiology, Adaptor Proteins, Signal Transducing, Antigens, CD19",
author = "Olaf Penack and Christophe Peczynski and Christian Koenecke and Emmanuelle Polge and Robin Sanderson and Ibrahim Yakoub-Agha and Nathalie Fegueux and Michael Daskalakis and Matthew Collin and Peter Dreger and Nicolaus Kr{\"o}ger and Urs Schanz and Adrian Bloor and Arnold Ganser and Caroline Besley and Wulf, {Gerald G} and Urban Novak and Ivan Moiseev and H{\'e}l{\`e}ne Schoemans and Basak, {Grzegorz W} and Christian Chabannon and Anna Sureda and Bertram Glass and Zinaida Peric",
note = "Copyright {\textcopyright} 2023 Penack, Peczynski, Koenecke, Polge, Sanderson, Yakoub-Agha, Fegueux, Daskalakis, Collin, Dreger, Kr{\"o}ger, Schanz, Bloor, Ganser, Besley, Wulf, Novak, Moiseev, Schoemans, Basak, Chabannon, Sureda, Glass and Peric.",
year = "2023",
doi = "10.3389/fimmu.2023.1252811",
language = "English",
volume = "14",
pages = "1252811",
journal = "FRONT IMMUNOL",
issn = "1664-3224",
publisher = "Lausanne : Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party

AU - Penack, Olaf

AU - Peczynski, Christophe

AU - Koenecke, Christian

AU - Polge, Emmanuelle

AU - Sanderson, Robin

AU - Yakoub-Agha, Ibrahim

AU - Fegueux, Nathalie

AU - Daskalakis, Michael

AU - Collin, Matthew

AU - Dreger, Peter

AU - Kröger, Nicolaus

AU - Schanz, Urs

AU - Bloor, Adrian

AU - Ganser, Arnold

AU - Besley, Caroline

AU - Wulf, Gerald G

AU - Novak, Urban

AU - Moiseev, Ivan

AU - Schoemans, Hélène

AU - Basak, Grzegorz W

AU - Chabannon, Christian

AU - Sureda, Anna

AU - Glass, Bertram

AU - Peric, Zinaida

N1 - Copyright © 2023 Penack, Peczynski, Koenecke, Polge, Sanderson, Yakoub-Agha, Fegueux, Daskalakis, Collin, Dreger, Kröger, Schanz, Bloor, Ganser, Besley, Wulf, Novak, Moiseev, Schoemans, Basak, Chabannon, Sureda, Glass and Peric.

PY - 2023

Y1 - 2023

N2 - We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.

AB - We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.

KW - Humans

KW - Immunotherapy, Adoptive/adverse effects

KW - Retrospective Studies

KW - Receptors, Chimeric Antigen

KW - Lymphoma, Large B-Cell, Diffuse/etiology

KW - Adaptor Proteins, Signal Transducing

KW - Antigens, CD19

U2 - 10.3389/fimmu.2023.1252811

DO - 10.3389/fimmu.2023.1252811

M3 - SCORING: Journal article

C2 - 37828980

VL - 14

SP - 1252811

JO - FRONT IMMUNOL

JF - FRONT IMMUNOL

SN - 1664-3224

ER -